Passage Bio gets FDA green light to add FTD-C9orf72 arm to PBFT02 trial

Passage BIO, Inc.

Positive Type C meeting feedback from FDA supports evaluating PBFT02 in FTD-C9orf72 patients.
Passage Bio to amend upliFT-D Phase 1/2 global study protocol to include FTD-C9orf72 population.
Company plans to initiate dosing of FTD-C9orf72 patients in first half of 2025.
FTD-C9orf72 affects an estimated 21,000 individuals in the U.S. and Europe.
PBFT02 already has FDA Fast Track and Orphan Drug designations; also Orphan from European Commission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.